Press Releases
Company files Information Statement with SEC
BETHESDA, MD – 18 December 2007: Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO) today announced that on 14 December 2007 it filed an Information Statement with the U.S. Securities and Exchange Commission (“SEC”). The Information Statement which will be provided to every stockholder of record as of 5 December 2007 advises stockholders that on 13 June 2007 the Board of Directors approved and recommended, and a majority of our stockholders consented to, resolutions to amend the Company’s Seventh Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of common and preferred stock, eliminating certain redundancies related to administration of the Board of Directors and to correct minor typographical errors in the Certificate of Incorporation. The Information Statement is only required to be sent to our stockholders for information purposes; no action from stockholders is required with respect thereto.
For further information, please contact:
Northwest Biotherapeutics
Anthony P. Deasey, Chief Financial Officer |
+ 1 240 497 9024 |
Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com)
/ Mary-Jane Johnson / Catherine Breen |
+44 (0)20 7466 5000 |
Collins Stewart
Tim Mickley / Adam Cowen |
+44 (0)20 7523 8350 |
|
